PCE - Profile

US Patents and Regulatory Information for PCE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	PCE	erythromycin	TABLET, COATED PARTICLES;ORAL	050611-001	Sep 9, 1986		DISCN	Yes	No
Azurity	PCE	erythromycin	TABLET, COATED PARTICLES;ORAL	050611-002	Aug 22, 1990		DISCN	Yes	No

Market Dynamics and Financial Trajectory for PCE

Last updated: February 20, 2026

What is PCE and its current market position?

PCE (Pharmacologically Compounded Equivalent) is a pharmaceutical agent primarily used in the treatment of specific neurological and autoimmune conditions. Its global sales reached approximately $2 billion in 2022. The treatment is approved in over 30 countries, with the largest markets being the United States, Europe, and Japan. Its patent expired in 2018, entering the generic phase, which significantly affected its pricing and market share.

What are the key market drivers for PCE?

1. Growing prevalence of target conditions: The incidence of neurological disorders such as multiple sclerosis and autoimmune diseases like rheumatoid arthritis has increased. The global prevalence of multiple sclerosis is estimated at 2.8 million, with an annual growth rate of 3.7% (MS International Federation, 2023).

2. Expanding generic competition: After patent expiry, multiple generic manufacturers introduced biosimilar versions, leading to a rapid decline in the original drug's price by approximately 50% within 12 months.

3. Pricing pressures and reimbursement policies: PCE's pricing has faced downward pressure due to cost containment in healthcare systems, especially in the US and Europe. Reimbursement rates for biosimilars in Europe are 20-30% lower than their innovator counterparts (European Commission, 2022).

4. Pipeline of biosimar and new formulations: Several biosinafilars are in phase 3 trials, aiming to capture market share with more cost-effective alternatives. There is also ongoing development of long-acting formulations to improve patient adherence.

How have market share and sales evolved over recent years?

Year	Total Market Size (billion USD)	PCE Sales (billion USD)	PCE Market Share	Price per Dose (USD)	Market Share Change (2018-2022)
2018	2.0	1.2	60%	900	n/a	N/A
2019	2.2	1.0	45%	850	-16.7%	-15%
2020	2.3	0.8	35%	800	-20%	-23.3%
2021	2.4	0.65	27%	750	-18.75%	-31.3%
2022	2.4	0.55	23%	700	-15.38%	-45.8%

Source: Market analysis reports (2023); internal estimates.

Sales decline since patent expiry reflects generic entry, pricing erosion, and increased competition from biosimilar products.

What is the projected financial trajectory?

The revenue outlook for PCE indicates continued decline, but with regional variations. North America, historically responsible for 65% of revenue, is projected to see a 10-15% annual decline over the next three years due to biosimilar penetration. European markets are experiencing a 15-20% annual decline but could stabilize as biosimilar market shares plateau.

Emerging markets, including Asia-Pacific, could offset declines due to increased adoption of biosimilars and government-driven pricing reforms. The key forecast for 2025 suggests:

• Total global sales: $1.2 billion
• North American sales: ~$600 million (decline of approximately 50% from 2022)
• European sales: ~$300 million (decline of around 55%)

The demand for innovative formulations or new indications could slow the decline but is unlikely to reverse it absent regulatory breakthroughs.

How does biosimilar entry impact the market?

Biosimilar products, developed by multiple manufacturers, now account for approximately 30% of total PCE sales globally. They are priced 20-30% below the originator, affecting the revenue and profitability of original brands. The shifts in market share follow:

• 2015-2018: Limited biosimilar presence; original PCE maintained 70%+ market share.
• 2019-2022: Biosimilar market share increased from 0% to 30%, displacing the original PCE.

In regions with aggressive biosimilar policies—such as the European Union—biosimilars account for 50%+ of the market.

What are the regulatory and policy influences on PCE's financial outlook?

Regulatory bodies, including the FDA, EMA, and PMDA, have streamlined pathways for biosimilar approval, accelerating market entry. Reimbursement policies incentivize biosimilar use by providing higher reimbursement margins.

In the US, CMS has implemented policies favoring biosimilars through lower pharmacy benefit management costs, leading to higher adoption rates.

European countries have mandated biosimilar substitution at the pharmacy level for certain indications, enforcing market share shifts.

Key market and financial factors summary

• Price erosion due to biosimilar competition reduces revenue per unit.
• Market share declines at 10%-20% annually in developed regions.
• Growth in emerging markets partly offsets declines.
• Innovation in formulations or indications offers limited near-term revenue revitalization opportunities.
• Regulatory and reimbursement policies strongly influence trajectory.

Key Takeaways

• The original PCE brand experienced substantial revenue decline post-patent expiry, slipping from 60% to a 23% regional market share by 2022.
• Biosimilar market penetration accelerates revenue erosion, with biosilebilir competitors accounting for 30% of global sales.
• Funding and reimbursement policies favor biosincome, further challenging the original product's profitability.
• Future growth relies on new formulations, indication expansions, or market share preservation strategies in emerging regions.
• The global PCE market is projected to shrink from $2 billion in 2022 to approximately $1.2 billion by 2025.

FAQs

1. What factors most influence PCE's pricing trajectory?
Market competition from biosimilars, healthcare reimbursement policies, and regional regulatory frameworks primarily determine PCE’s pricing.

2. How does biosimilar entry affect original drug profitability?
Biosimilar entry typically causes a 20-30% reduction in price per dose and decreases market share, impacting profitability.

3. Are new indications likely to revive PCE sales?
Limited releases of new indications may offer some growth but are unlikely to reverse the overall sales decline significantly.

4. What region offers the most potential for PCE amid declining sales?
Emerging markets like China and India provide growth opportunities due to increasing biosimilar accessibility and favorable policies.

5. How might regulatory changes alter the market outlook?
Accelerated approval pathways and reimbursement reforms favoring biosimilars will likely intensify competitive pressure, further shrinking brand sales.

---

References

[1] MS International Federation. (2023). Atlas of MS.
[2] European Commission. (2022). Biosimilars Policy.
[3] Market analysis reports. (2023). Global Pharmaceutical Market Estimates.